KLF2 is identified as a required mediator for statin-induced eNOS and thrombomodulin expression in endothelial cells, presenting a potential therapeutic target for vascular disease.
Taken together, these observations indicate that statin-dependent induction of eNOS and thrombomodulin requires KLF2 and thereby provides a novel molecular target for modulating endothelial function in vascular disease.
SenBanerjee et al. (Tue,) studied this question.